Literature DB >> 17583571

Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964-2003.

Ingemar Turesson1, Martha S Linet, Magnus Björkholm, Sigurdur Y Kristinsson, Lynn R Goldin, Neil E Caporaso, Ola Landgren.   

Abstract

Population-based cancer registries are widely used to provide key information about cancer incidence, survival, determinants of progression and clues about pathogenesis. To substantially expand the limited data on diagnostic accuracy and completeness for lymphoproliferative (LP) tumors in such databases, we conducted a retrospective investigation of close to 1,000 cases diagnosed during 4 decades in Sweden. We identified and reviewed medical records for 494 LP tumor patients reported to the population-based Swedish Cancer registry and 503 LP tumor patients identified from hospitals in Sweden among patients with LP tumors diagnosed during 1964-2003. The stratified samples were randomly selected from patients according to LP subtype, over 4 equal calendar periods, and among 6 selected hospitals of diverse size and from different geographic regions. We found 97.9% of reported LP tumor cases to fulfill current diagnostic criteria for having an LP tumor and observed 89.7% to have accurate LP tumor subtype. The overall completeness of non-Hodgkin lymphoma, Hodgkin lymphoma and multiple myeloma cases in the Cancer registry was 95-99% but was lower for the more indolent tumors, chronic lymphocytic leukemia (87.9%) and Waldenström's macroglobulinemia (68.1%). We observed increased overall under-ascertainment for patients diagnosed above age 80 (27%) and among individuals diagnosed before 1973 (12%). In conclusion the diagnostic accuracy and completeness for classically defined LP tumor entities in the Swedish Cancer registry is high. However, we found under-ascertainment of patients with indolent LP tumors, particularly among patients diagnosed at older ages, with early-stage disease and diagnosed in earlier years. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2007        PMID: 17583571     DOI: 10.1002/ijc.22912

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  52 in total

1.  Cancer risk among patients with myotonic muscular dystrophy.

Authors:  Shahinaz M Gadalla; Marie Lund; Ruth M Pfeiffer; Sanne Gørtz; Christine M Mueller; Richard T Moxley; Sigurdur Y Kristinsson; Magnus Björkholm; Fatma M Shebl; James E Hilbert; Ola Landgren; Jan Wohlfahrt; Mads Melbye; Mark H Greene
Journal:  JAMA       Date:  2011-12-14       Impact factor: 56.272

Review 2.  Familial aggregation of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia with solid tumors and myeloid malignancies.

Authors:  Sigurdur Y Kristinsson; Lynn R Goldin; Ingemar Turesson; Magnus Björkholm; Ola Landgren
Journal:  Acta Haematol       Date:  2012-02-03       Impact factor: 2.195

3.  Elevated risk of chronic lymphocytic leukemia and other indolent non-Hodgkin's lymphomas among relatives of patients with chronic lymphocytic leukemia.

Authors:  Lynn R Goldin; Magnus Björkholm; Sigurdur Y Kristinsson; Ingemar Turesson; Ola Landgren
Journal:  Haematologica       Date:  2009-03-13       Impact factor: 9.941

4.  Autoimmunity and risk for Hodgkin's lymphoma by subtype.

Authors:  Sigurdur Y Kristinsson; Ola Landgren; Jan Sjöberg; Ingemar Turesson; Magnus Björkholm; Lynn R Goldin
Journal:  Haematologica       Date:  2009-10       Impact factor: 9.941

5.  Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study.

Authors:  Sigurdur Y Kristinsson; Ruth M Pfeiffer; Magnus Björkholm; Lynn R Goldin; Sam Schulman; Cecilie Blimark; Ulf-Henrik Mellqvist; Anders Wahlin; Ingemar Turesson; Ola Landgren
Journal:  Blood       Date:  2010-03-18       Impact factor: 22.113

6.  Patterns of survival in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia: a population-based study of 1,555 patients diagnosed in Sweden from 1980 to 2005.

Authors:  Sigurdur Y Kristinsson; Sandra Eloranta; Paul W Dickman; Therese M-L Andersson; Ingemar Turesson; Ola Landgren; Magnus Björkholm
Journal:  Am J Hematol       Date:  2012-11-19       Impact factor: 10.047

7.  Increased risk for non-Hodgkin lymphoma in individuals with celiac disease and a potential familial association.

Authors:  Ying Gao; Sigurdur Y Kristinsson; Lynn R Goldin; Magnus Björkholm; Neil E Caporaso; Ola Landgren
Journal:  Gastroenterology       Date:  2008-09-25       Impact factor: 22.682

8.  Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.

Authors:  Ola Landgren; Lynn R Goldin; Sigurdur Y Kristinsson; Elin A Helgadottir; Jan Samuelsson; Magnus Björkholm
Journal:  Blood       Date:  2008-05-01       Impact factor: 22.113

9.  Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study.

Authors:  Sigurdur Y Kristinsson; Magnus Björkholm; Therese M-L Andersson; Sandra Eloranta; Paul W Dickman; Lynn R Goldin; Cecilie Blimark; Ulf-Henrik Mellqvist; Anders Wahlin; Ingemar Turesson; Ola Landgren
Journal:  Haematologica       Date:  2009-07-16       Impact factor: 9.941

10.  Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden.

Authors:  Ola Landgren; Sigurdur Y Kristinsson; Lynn R Goldin; Neil E Caporaso; Cecilie Blimark; Ulf-Henrik Mellqvist; Anders Wahlin; Magnus Bjorkholm; Ingemar Turesson
Journal:  Blood       Date:  2009-01-30       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.